These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 1495553)

  • 41. Damon to form separate lab and biotech companies.
    Wagner M
    Mod Healthc; 1988 Apr; 18(18):5. PubMed ID: 10287267
    [No Abstract]   [Full Text] [Related]  

  • 42. Vouchers for FDA priority reviews.
    Spatz ID
    Health Aff (Millwood); 2006; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
    [No Abstract]   [Full Text] [Related]  

  • 43. FDA: biotech friend or foe?
    Lamont A
    Biotechnology (N Y); 1991 Mar; 9(3):248, 250. PubMed ID: 1367299
    [No Abstract]   [Full Text] [Related]  

  • 44. Western biotechs ponder follow-on possibilities.
    Waltz E
    Nat Biotechnol; 2008 Sep; 26(9):962-3. PubMed ID: 18779793
    [No Abstract]   [Full Text] [Related]  

  • 45. Beyond the lab in biotech. With so many drugs in trial, new jobs are opening up.
    Carmichael M
    Newsweek; 2002 Sep; 140(13):53. PubMed ID: 12375414
    [No Abstract]   [Full Text] [Related]  

  • 46. What's fueling the biotech engine?
    Aggarwal S
    Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
    [No Abstract]   [Full Text] [Related]  

  • 47. Biotech R&D still reeling.
    Lawrence S
    Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
    [No Abstract]   [Full Text] [Related]  

  • 48. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 49. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA user fee law poised for passage in Congress but not without stirring up controversy.
    Finkelstein J
    J Natl Cancer Inst; 2007 Jul; 99(14):1072-3. PubMed ID: 17623792
    [No Abstract]   [Full Text] [Related]  

  • 51. Betting on biogenerics.
    Dove A
    Nat Biotechnol; 2001 Feb; 19(2):117-20. PubMed ID: 11175723
    [No Abstract]   [Full Text] [Related]  

  • 52. Biotechnology drugs create new maze of concerns for hospitals.
    Lumsdon K
    Hospitals; 1991 Dec; 65(23):32, 34-5. PubMed ID: 1937456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Whatever happened to user fees and the FDA's promise to expedite new drug approvals?
    Gatty B
    Hosp Formul; 1993 Jul; 28(7):656, 655. PubMed ID: 10127048
    [No Abstract]   [Full Text] [Related]  

  • 54. US FDA seeks more pharmaceutical industry cash.
    Zwillich T
    Lancet; 2007 Feb; 369(9559):357. PubMed ID: 17283497
    [No Abstract]   [Full Text] [Related]  

  • 55. The Prescription Drug User Fee Act of 1992: speeding up the drug approval process.
    Bierut MB
    Healthspan; 1992 Dec; 9(11):12-4. PubMed ID: 10123552
    [No Abstract]   [Full Text] [Related]  

  • 56. Biotech blockbusters consolidate markets.
    Lawrence S
    Nat Biotechnol; 2006 Dec; 24(12):1466. PubMed ID: 17160033
    [No Abstract]   [Full Text] [Related]  

  • 57. FDA transparency rules could hit small companies hardest.
    Allison M
    Nat Biotechnol; 2010 Aug; 28(8):767-8. PubMed ID: 20697386
    [No Abstract]   [Full Text] [Related]  

  • 58. A testing approach based on tiny doses still awaits big results.
    Coombs A
    Nat Med; 2008 Aug; 14(8):796. PubMed ID: 18685584
    [No Abstract]   [Full Text] [Related]  

  • 59. Amgen asks judge for speedy ruling in patent case.
    Nephrol News Issues; 1999 Dec; 13(12):14. PubMed ID: 11984928
    [No Abstract]   [Full Text] [Related]  

  • 60. User-fee boost would up safety, reputations. A new paper suggests that drug makers, FDA can't afford not to raise user fees.
    Med Health; 2005 Oct; 59(39):2, 4. PubMed ID: 16279192
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.